Department of Urology, Medical Faculty Carl Gustav Carus, TU Dresden, Fetscherstr. 74, 01307, Dresden, Germany.
Department of Urology, University Hospital Frankfurt, Frankfurt am Main, Germany.
World J Urol. 2020 Jul;38(7):1701-1709. doi: 10.1007/s00345-019-02956-8. Epub 2019 Sep 17.
To compare long-term functional outcomes after robotic vs. retropubic RP for patients with localized prostate cancer in routine care.
"HAROW" was a large German noninterventional health services research study that prospectively evaluated the treatment of patients with localized prostate cancer (≤ T2c). We sent validated questionnaires to 1260 patients who underwent RP to evaluate long-term outcomes.
After a median follow-up of 6.3 [interquartile range (IQR) 4.8-7.6] years, 42 (3%) patients had died. The return rate of the questionnaire was 76.8% (936/1218). The approach was robotic in 404 and retropubic in 532 patients. In the multivariate analysis, lack of postoperative radiotherapy [odds ratio (OR) 3.1], younger patient age (< 60 years: OR 2.8; 60-69 years: OR 2.1), preoperative urinary continence (OR 2.4), and higher annual hospital caseload (≥ 200 cases: OR 1.6) were independent predictors of urinary continence. The potency rate after nerve-sparing RP in preoperatively potent men was 40.5% (111/274). In the multivariate analysis, younger patient age (< 60 years: OR 17.9; 60-69 years: OR 8.0), lower oncologic risk (OR 2.8), and lack of postoperative radiotherapy (OR 2.2) were independent predictors of potency.
Younger age and lack of postoperative radiotherapy were associated with better urinary continence and erectile function. Additionally, a high annual caseload (≥ 200 RP/year) was associated with better urinary continence. Younger age, low or intermediated oncological risk and lack of postoperative radiotherapy were independent predictors for a trifecta outcome. The surgical approach did not affect long-term functional outcomes.
在常规护理中比较机器人辅助与经耻骨后前列腺切除术(retropubic RP)治疗局限性前列腺癌患者的长期功能结局。
“HAROW”是一项大型德国非介入性卫生服务研究,前瞻性评估了局限性前列腺癌(≤T2c)患者的治疗方法。我们向接受 RP 治疗的 1260 名患者发送了经过验证的问卷,以评估长期结果。
中位随访 6.3 年后(四分位距 [IQR] 4.8-7.6),42 名(3%)患者死亡。问卷的回复率为 76.8%(936/1218)。手术方式为机器人辅助 404 例,经耻骨后 532 例。多变量分析显示,术后未行放疗[比值比(OR)3.1]、患者年龄较轻(<60 岁:OR 2.8;60-69 岁:OR 2.1)、术前尿控功能正常(OR 2.4)和医院年手术量较高(≥200 例:OR 1.6)是尿控的独立预测因素。术前有勃起功能的神经保留 RP 后勃起功能恢复率为 40.5%(111/274)。多变量分析显示,患者年龄较轻(<60 岁:OR 17.9;60-69 岁:OR 8.0)、肿瘤风险较低(OR 2.8)和未行术后放疗(OR 2.2)是勃起功能恢复的独立预测因素。
年轻和缺乏术后放疗与更好的尿控和勃起功能相关。此外,较高的年手术量(≥200 例 RP/年)与更好的尿控相关。年轻、低或中危肿瘤及缺乏术后放疗是三重结局的独立预测因素。手术方式并不影响长期功能结局。